Proton Pump Inhibitor-induced Gut Dysbiosis and Immunomodulation: Current Knowledge and Potential Restoration by Probiotics

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2023 May 4

PMID 37142877

Authors

Aneta Kiecka

Marian Szczepanik

Affiliations

Soon will be listed here.

Abstract

Proton pump inhibitors (PPIs) are the most commonly prescribed drugs for the treatment of non-erosive reflux disease (NERD), ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), esophagitis, peptic ulcer disease (PUD), Zollinger-Ellison syndrome (ZES), gastroesophageal reflux disease (GERD), non-ulcer dyspepsia, and Helicobacter pylori eradication therapy. The drugs have the effect of inhibiting acid production in the stomach. According to research, PPIs can affect the composition of gut microbiota and modulate the immune response. Recently, there has been a problem with the over-prescription of such drugs. Although PPIs do not have many side effects, their long-term use can contribute to small intestinal bacterial overgrowth (SIBO) or C. difficile and other intestinal infections. Probiotic supplementation during PPIs therapy may provide some hope in the reduction of emerging therapy side effects. This review aims to present the most important effects of long-term PPI use and provides critical insights into the role of probiotic intervention in PPI therapy.

Citing Articles

Rising of natural therapies: Potential and challenges of traditional Chinese medicine in the management of gastrointestinal diseases.

Tian X, Zhan J, Qiao C, Ge J, Li D World J Gastroenterol. 2025; 31(9):103145.

PMID: 40061595 PMC: 11886042. DOI: 10.3748/wjg.v31.i9.103145.

Why think twice before prescribing proton pump inhibitors.

Lemmens A, Huysentruyt K, Vandenplas Y Eur J Pediatr. 2025; 184(3):227.

PMID: 40042553 DOI: 10.1007/s00431-025-06058-z.

The role of an anti-reflux diet in the treatment of chronic cough caused by laryngopharyngeal reflux.

Hrankova V, Balner T, Konde A, Gubova P, Zelenik K, Kominek P Eur Arch Otorhinolaryngol. 2025; .

PMID: 39994032 DOI: 10.1007/s00405-025-09258-3.

Risks of anti- therapy and long-term therapy with antisecretory drugs.

Kotelevets S World J Gastroenterol. 2025; 31(4):101933.

PMID: 39877710 PMC: 11718649. DOI: 10.3748/wjg.v31.i4.101933.

Salivary microbiota composition before and after use of proton pump inhibitors in patients with laryngopharyngeal reflux: a self-control study.

Cui X, Yin L, Zhang Y, Jiang X, Li L, Bi X BMC Oral Health. 2024; 24(1):1194.

PMID: 39379876 PMC: 11460238. DOI: 10.1186/s12903-024-05000-3.

References

Belei O, Olariu L, Dobrescu A, Marcovici T, Marginean O . Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?. J Neurogastroenterol Motil. 2018; 24(1):51-57. PMC: 5753903. DOI: 10.5056/jnm17059. View

Amir I, Konikoff F, Oppenheim M, Gophna U, Half E . Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol. 2013; 16(9):2905-14. DOI: 10.1111/1462-2920.12285. View

Pavlovic N, Stankov K, Mikov M . Probiotics--interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol. 2012; 168(7):1880-95. DOI: 10.1007/s12010-012-9904-4. View

Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J . Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010; 16(24):2978-90. PMC: 2890937. DOI: 10.3748/wjg.v16.i24.2978. View

Hegar B, Hutapea E, Advani N, Vandenplas Y . A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole. J Pediatr (Rio J). 2013; 89(4):381-7. DOI: 10.1016/j.jped.2012.12.005. View

Nelis G, Engelage A, Samson G . Does long-term inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth?. Neth J Med. 1994; 45(3):93-100. View

Cortes J, Rivas M, Molina-Infante J, Gonzalez-Nunez M, Perez-G M, Masa J . Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. J Allergy Clin Immunol. 2009; 124(3):607-10, 610.e1. DOI: 10.1016/j.jaci.2009.06.023. View

Tsuda A, Suda W, Morita H, Takanashi K, Takagi A, Koga Y . Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. Clin Transl Gastroenterol. 2015; 6:e89. PMC: 4816248. DOI: 10.1038/ctg.2015.20. View

Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H . The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005; 509(2-3):201-10. DOI: 10.1016/j.ejphar.2004.12.042. View

10.

Woodard G, Encarnacion B, Downey J, Peraza J, Chong K, Hernandez-Boussard T . Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J Gastrointest Surg. 2009; 13(7):1198-204. DOI: 10.1007/s11605-009-0891-x. View

11.

Jandhyala S, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy D . Role of the normal gut microbiota. World J Gastroenterol. 2015; 21(29):8787-803. PMC: 4528021. DOI: 10.3748/wjg.v21.i29.8787. View

12.

Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K . Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996; 39(1):54-9. PMC: 1383231. DOI: 10.1136/gut.39.1.54. View

13.

Delarocque-Astagneau E, Bouillant C, Vaillant V, Bouvet P, Grimont P, Desenclos J . Risk factors for the occurrence of sporadic Salmonella enterica serotype typhimurium infections in children in France: a national case-control study. Clin Infect Dis. 2000; 31(2):488-92. DOI: 10.1086/313990. View

14.

Barrett J, Canale K, Gearry R, Irving P, Gibson P . Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol. 2008; 14(32):5020-4. PMC: 2742929. DOI: 10.3748/wjg.14.5020. View

15.

Lamas A, Regal P, Vazquez B, Cepeda A, Franco C . Short Chain Fatty Acids Commonly Produced by Gut Microbiota Influence Motility, Biofilm Formation, and Gene Expression. Antibiotics (Basel). 2019; 8(4). PMC: 6963744. DOI: 10.3390/antibiotics8040265. View

16.

Plaza-Diaz J, Ruiz-Ojeda F, Gil-Campos M, Gil A . Mechanisms of Action of Probiotics. Adv Nutr. 2019; 10(suppl_1):S49-S66. PMC: 6363529. DOI: 10.1093/advances/nmy063. View

17.

Al-nassir W, Sethi A, Nerandzic M, Bobulsky G, Jump R, Donskey C . Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008; 47(1):56-62. DOI: 10.1086/588293. View

18.

Otte J, Podolsky D . Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol. 2004; 286(4):G613-26. DOI: 10.1152/ajpgi.00341.2003. View

19.

Singh A, Cresci G, Kirby D . Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018; 33(5):614-624. DOI: 10.1002/ncp.10181. View

20.

Shi S, Klotz U . Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64(10):935-51. DOI: 10.1007/s00228-008-0538-y. View